Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT167
- Development stage
- Preclinical
- Lead developer
- Palisades Therapeutics
- Modality
- Small Molecules
01
Overview
PT167 is a preclinical-stage small molecule therapeutic being developed by Palisades Therapeutics. It is designed as a dual modulator of the glucocorticoid receptor (GR) and the androgen receptor (AR), two nuclear receptors that are frequently implicated in the progression and treatment resistance of various cancers. By targeting both receptors simultaneously, PT167 aims to provide a more comprehensive approach to inhibiting hormonal signaling pathways that drive tumor growth, particularly in cases where resistance to standard-of-care hormonal therapies has developed. The drug is currently positioned for development within the field of oncology.
02
Targets
AR (Adrenergic receptors)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on PT167.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT167.